Apatinib treatment for symptomatic pseudoprogression after standard treatment for glioblastoma multiforme: a case report

• Published in: Annals of palliative medicine Vol. 8; no. 5; pp. 752 - 757
• Main Authors: Wang, Zheng, Du, Fangfang, Sun, Yafang, Guo, Yang, Song, Bin, Wang, Yahong, Shi, Xiangyu, Jiang, Wei
• Format: Journal Article
• Language: English
• Published: China 01.11.2019
• Subjects: Apatinib; pseudoprogression; bevacizumab; glioblastoma
• ISSN: 2224-5820; 2224-5839
• DOI: 10.21037/apm.2019.11.13

Apatinib, a novel tyrosine kinase inhibitor, has anti-angiogenetic effect just as bevacizumab. Although bevacizumab has been used successfully in treating cerebral radiation necrosis, there has yet not any report on that apatinib can treat pseudoprogression with symptoms. Here we report a case of glioblastoma multiforme (GBM) patient with pseudoprogression after receiving the concurrent chemoradiotherapy, which was successfully treated by apatinib. A 51-year-old woman had multiple intracranial lesions (left parietal and right frontal), the primary left parietal lesion was surgically removed and was pathologically confirmed as glioblastoma (WHO grade IV). Then the patient received postoperative temozolomide with concurrent chemoradiotherapy. Three weeks after the radiotherapy, the patient experienced increased intracranial pressure and seizure. Magnetic resonance imaging (MRI) T1 enhancement examination showed an increase of abnormal enhancement range in the area of irradiation. After multiple disciplinary team (MDT) discussion, the patient was diagnosed with pseudoprogression after radiotherapy. Then she was given apatinib for 8 weeks at a dose of 500 mg qd. During the treatment period, the clinical symptoms and corresponding nerve images of the patient have been rapidly improved. In 12 months after the radiotherapy, progression of tumor in the primary site has not been discovered. Apatinib showed a good therapeutic effect and tolerance for the development of pseudoprogression advances with obvious symptoms.